Sharemaestro Newsreel

Sei Investments Co. Has $132.65 Million Stake in West Pharmaceutical Services, Inc. $WST

Sei Investments Co. has a significant stake worth $132.65 million in West Pharmaceutical Services, Inc., despite trimming its holdings by 10.6% in the first quarter. The medical instruments supplier has shown strong financial performance, beating Q2 expectations with EPS of $2.37 and revenue of …

First Trust Advisors LP Acquires 57,931 Shares of LeMaitre Vascular, Inc. $LMAT

First Trust Advisors LP increased its stake in LeMaitre Vascular (NASDAQ:LMAT) by 6.2% during the first quarter, now holding 998,071 shares valued at $108.96 million. Other institutional investors also adjusted their positions in the company, while insiders have sold shares totaling over $5.9 million …

CooperCompanies stock trades steadily as contact lens growth supports earnings

CooperCompanies' stock remains stable, driven by increased revenue from its CooperVision (contact lenses) and CooperSurgical (women's health) divisions. The company's fiscal 2025 results show a 7% year-over-year revenue growth to $3.1 billion, with robust operating margins and strong cash flow supporting ongoing investment and …

Intuitive Surgical Inc (ISRG) turnover swells as weekly loss hits 15.1%

The robotic-surgery maker’s setback has pushed the 12-week return deeper into negative territory, with trend support still absent.

West Pharmaceutical Delivers Another Beat - But The Real Story Is The Mix Shift (NYSE:WST)

ZTEK Q3 2023 Earnings: Narrower-Than-Expected Loss Drives Stock Higher - Analyst Drop Coverage

Nyxoah (NYXH) Q1 2026 Earnings: EPS Beat Narrowes Losses, Shares Dip as Market Awaits Revenue Milestones

Nyxoah (NYXH) Q1 2026 Earnings: Narrowed Loss Beats Estimates, Shares Dip 4.76% - Earnings Sentiment Score

West Pharmaceutical Earnings: Another Strong Quarter and Upward Guidance Revision

What is HC Wainwright's Estimate for BLFS Q1 Earnings?

Avantor, Inc. (AVTR) Stock forecasts

Argus provides a report on Avantor, Inc. (AVTR), a provider of products and services to customers in various industries, including biopharma and healthcare. The report includes an earnings estimate rating and a current price of $11.44 for AVTR stock. The article encourages users to …

Utah Medical: Q2 Earnings Snapshot

This article provides a Q2 earnings snapshot for Utah Medical. The content is explicitly minimal, containing only the title and a note about being "Powered and protected by Privacy," along with image references. No substantive financial data or details are available in the provided …

Price to sales forward of NexGel, Inc – NASDAQ:NXGL

This page displays the "Price to sales forward" financial metric for NexGel, Inc (NASDAQ:NXGL) on TradingView. It indicates that the market was closed at the time of viewing with no trades. The article is primarily a financial data display page with navigational elements and …

AtriCure 2Q Net $8.96M >ATRC

This article states that AtriCure's second quarter net income was $8.96 million. The article headline seems to be the entire content provided.

UBS Adjusts Price Target on Align Technology to $189 From $186, Maintains Neutral Rating

UBS has adjusted its price target for Align Technology (ALGN) shares to $189 from $186, while reiterating its Neutral rating on the stock. This update reflects a modest revision in the valuation outlook for the company by the financial firm.

2 Top Growth Stocks to Buy Right Now Without Any Hesitation

Key Points Eli Lilly has just begun tapping into the massive opportunity in chronic weight management. Intuitive Surgical can bounce back thanks to innovation, a strong moat, and a large addressable market. 10 stocks we like better than Eli Lilly › Some stocks look …

3 Reasons to Sell XRAY and 1 Stock to Buy Instead

This article recommends selling Dentsply Sirona (XRAY) due to declining constant currency revenue, decreasing earnings per share, and negative return on invested capital. The company's recent stock performance has lagged the market, and despite an "optically cheap" valuation, its fundamental issues suggest significant downside. …

Repligen Corporation (RGEN) stock price, news, quote and history

This page provides a comprehensive overview of Repligen Corporation (RGEN) stock, including its current price, news, historical data, and financial analysis. It details the company's bioprocessing technologies and systems, product offerings, and recent financial performance, alongside analyst insights and comparisons with similar companies.

BIOLIFE SOLUTIONS INC : JEFFERIES CUTS TO HOLD FROM BUY; RAISES TARGET PRICE TO $31 FROM $30

Jefferies has changed its rating for Biolife Solutions Inc. (BLFS.O) from "buy" to "hold." Despite the downgrade, the investment bank increased its target price for the company's stock to $31 from its previous estimate of $30. This adjustment reflects a nuanced view from Jefferies …

Enterprise value to revenue forward of NexGel, Inc – NASDAQ:NXGL

This article provides financial information for NexGel, Inc (NASDAQ: NXGL) from TradingView, specifically focusing on its enterprise value to revenue forward. It presents a table with the period, value, change, and percentage change for this metric. The page also includes general market data and …

From Signal to Action: How Alcon and Redica Systems Put Real-Time Regulatory Intelligence Into Practice

This article discusses how Alcon and Redica Systems are transforming regulatory intelligence in the medtech industry from a reactive, manual process to a proactive, automated one. It highlights three stages: early policy intake and advocacy, impact assessment using AI for conditional workflows, and seamless …

Yorkville Advisors Global LP Invests $1.91 Million in OraSure Technologies, Inc. $OSUR

Yorkville Advisors Global LP has invested $1.91 million in OraSure Technologies, Inc. (OSUR) by purchasing 635,000 shares, representing 1.2% of Yorkville's portfolio. Despite this new institutional interest, analyst sentiment remains cautious with a "Reduce" consensus rating and a $3.00 target price. Concurrently, an insider, …

AtriCure targets $602M-$610M 2026 revenue while raising adjusted EBITDA outlook to $85M-$89M

Earnings Call Insights: AtriCure (ATRC) Q2 2026 MANAGEMENT VIEW * "AtriCure delivered solid second quarter results with worldwide revenue of $154 million and growth of 13%." (CEO, President & Director Michael H. Carrel) Carrel said U.S. growth was "fueled by continued adoption" across pain …

Avantor Inc (AVTR) Stock Up 3.6% and Still Undervalued -- GF Sco

Avantor Inc (AVTR) shares rose 3.6% to $11.35 and are considered undervalued by approximately 38.4% according to GuruFocus' GF Value™ of $18.43, despite a "possible value trap" warning. The company has a GF Score™ of 61/100, indicating an "above average" rating, with insiders recently …

US589889AA2 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the US589889AA2 bond issued by Merit Medical Systems, Inc. It highlights that the bond has a current coupon rate of 3.00% and its next payment is scheduled for August 3, 2026. The page offers an overview of …

US589889AA2 Bond Risk Profile

This page provides a risk profile for the Merit Medical Systems, Inc. 3.0% 01-FEB-2029 bond, identified as US589889AA2 on the Frankfurt Stock Exchange. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help users evaluate the …

Microbot Medical Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026

Microbot Medical announced significant growth in Q2 2026, with over 100% increases in revenue, customer base, and procedure volume compared to the previous year. The company's progress is highlighted by the continued development of its core products, including the LIBERTY® Robotic System, which is …

AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say

AtriCure (ATRC) reported $153.6 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 12.8%. EPS of $0.18 for the same period compares to -$0.02 a year ago. The reported revenue represents a surprise of +1.39% over the Zacks Consensus …

AtriCure Releases Q2 2026 Financial Results

AtriCure, Inc. reported strong Q2 2026 financial results, with adjusted EPS of $0.18, significantly beating analyst estimates, and revenue of $153.6M, exceeding expectations. This performance represents a 12.8% increase in revenue year-over-year, driven by robust demand for their cardiac ablation technologies. The company provided …

Earnings call transcript: AtriCure tops Q2 2026 estimates, shares fall after hours

AtriCure Inc. reported strong second-quarter 2026 results, beating Wall Street expectations for both profit and revenue, primarily driven by growth in pain management, appendage management, and open ablation. Despite the positive financial performance and improved gross margins, the company's shares fell after hours, reflecting …

Innovative Eyewear (Nasdaq: LUCY) registers 6,766,673 warrant shares

Innovative Eyewear, Inc. (Nasdaq: LUCY) has registered 6,766,673 shares of common stock for resale, which are issuable upon the exercise of outstanding Series J Investor Warrants and placement agent warrants. While the company will not receive proceeds from the resale of these shares by …

AtriCure Q2 Earnings Call Highlights

AtriCure reported strong Q2 2026 results with double-digit revenue growth and a return to GAAP profitability, driven by its pain management, appendage management, and open ablation franchises. The company raised its full-year adjusted EBITDA outlook, anticipating continued growth from these key areas while acknowledging …

AtriCure Reports Q2 2026 Results: Full Earnings Call Transcript

AtriCure (NASDAQ: ATRC) announced its Q2 2026 financial results, reporting worldwide revenue of $154 million, a 13% increase, and a U.S. revenue increase of 14%, driven by strong adoption of key products across its pain management, appendage management, and open ablation franchises. The company …

AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates

AtriCure (ATRC) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

embecta's fiscal Q3 call includes an operational update and Q&A

Embecta (Nasdaq: EMBC) is scheduled to host a conference call on Friday, August 7, 2026, at 8:00 a.m. ET to discuss its fiscal third-quarter 2026 financial results. The call will also include an operational update and a Q&A session for participants. A webcast replay …

embecta to Report Fiscal Third Quarter Financial Results

Embecta Corp. (Nasdaq: EMBC) will host a conference call on Friday, August 7, 2026, at 8:00 a.m. ET to discuss its fiscal third quarter 2026 financial results and provide an operational update. The call will also include a question and answer session. Interested parties …